Entheon Biomedical
  • CSE:ENBI
  • OTC:ENTBF
  • ABOUT ENTHEON
  • REASONS TO BELIEVE
  • TEAM
  • INVESTORS
    • SHARE STRUCTURE
    • STOCK INFORMATION
    • FINANCIAL STATEMENTS
    • PRESS RELEASES & NEWS
  • CONTACT
Select Page
Entheon Biomedical is featured on Double Blind Magazine

Entheon Biomedical is featured on Double Blind Magazine

by Entheogen Biomedical | Apr 8, 2020 | Company News, Uncategorized

DMT (N-dimethyltryptamine) is known to occasion among the most intense of psychedelic experiences: For some it offers a blastoff into another dimension, an opportunity to “meet God”—or aliens. It can be transformative, mystical, or scary, but the effects only last...

Recent Posts

  • Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
  • Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial
  • Entheon Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
  • When Will Psychedelics be Legal in the United States?
  • MPV annonce l’approbation conditionnelle de sa transaction avec Entheon Biomedical Corp. par le CSE

Recent Comments

    Archives

    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020
    • April 2020
    • February 2020
    • December 2019
    • November 2019
    • July 2019
    • April 2019
    • December 2018
    • February 2018
    • January 2018

    Categories

    • Company News
    • Industry News
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Entheon Biomedical 2020 © All rights reserved | Website by S3 Communications | Terms & Privacy